Blood thinning deal

Ever since the $52bn US pharmaceuticals group ousted its chief executive in September, it has been de facto on the block. Given their joint Plavix arrangement, Sanofi looks in pole position to pounce.
Ever since the $52bn US pharmaceuticals group ousted its chief executive in September, it has been de facto on the block. Given their joint Plavix arrangement, Sanofi looks in pole position to pounce.
Required fields *